Irak degraders and uses thereof

A compound of formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• Rx is selected from C1-6 aliphatic and —OC1-6 aliphatic;
• x is 0 or 1;
• L is —(C1-10 aliphatic)-NR—(C1-10aliphatic)-, -Cy-NR—(C1-10 aliphatic)-, -Cy-(C1-10 aliphatic)-NR—(C1-10 aliphatic)-, —(C1-10 aliphatic)-Cy-NR—(C1-10 aliphatic)-, —(C1-10 aliphatic)-Cy-(C1-10 aliphatic)-NR—(C1-10 aliphatic)-, -Cy-(C1-10 aliphatic)-Cy-NR—(C1-10 aliphatic)-, -Cy-(C1-10 aliphatic)-NR-Cy-(C1-10 aliphatic)-, —(C1-10 aliphatic)-O—(C1-10aliphatic)-, -Cy-O—(C1-10 aliphatic)-, -Cy-(C1-10 aliphatic)-O—(C1-10 aliphatic)-, —(C1-10 aliphatic)-Cy-O—(C1-10 aliphatic)-, —(C1-10 aliphatic)-Cy-(C1-10 aliphatic)-O—(C1-10 aliphatic)-, -Cy-(C1-10 aliphatic)-Cy-O—(C1-10 aliphatic)-, -Cy-(C1-10 aliphatic)-O-Cy-(C1-10 aliphatic)-, -Cy-(C1-10 aliphatic)-, —(C1-10 aliphatic)-Cy-(C1-10 aliphatic)-, -Cy-(C1-10 aliphatic)-Cy-(C1-10 aliphatic)-, or —(C1-10 aliphatic)-Cy-(C1-10 aliphatic)-Cy-(C1-10 aliphatic)-, wherein:
• each -Cy- is independently a bivalent ring selected from a 4-7 membered saturated carbocyclylenyl, a 7-11 membered saturated spiro carbocyclylenyl, a 4-7 membered saturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-11 membered saturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic saturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein each -Cy- is optionally substituted with 1-2 fluoro or methyl;
• and
• IRAK is an IRAK4 binding moiety of the following structure:
• or a pharmaceutically acceptable salt thereof, wherein:
• Ring A is cyclobutyl or cyclohexyl;
• Ring B is phenyl,
• Ring C is phenyl or a 5-10 membered mono- or bicyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
• each of L2 and L3 is a covalent bond;
• R1 is hydrogen, C1-6 alkyl, fluoro, chloro, —CN, —OR, —CFR2, —CF2(R), —CF3, —CR2(OR), —C(O)OR, or —C(O)NR2;
• each R2 is independently hydrogen, C1-6 alkyl, fluoro, chloro, —CN, —OR, —NR2, —CFR2, —CF2 (R), or —CF3;
• each R is independently selected from hydrogen, or a group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
• R4 is selected from hydrogen or a 5-11 membered saturated or partially unsaturated bicyclic, bridged bicyclic, or spiro heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
• n is 0 or 1;
• and
• m is 0, 1, or 2.